In 2023, a peer-reviewed study reported that a trace breakdown product of sucralose broke chromosomes in human white blood cells, in two separate laboratory assays. The same paper then ran the test regulators actually rely on to flag heritable mutation risk. That test came back negative.
Three years later, neither the FDA nor the EU's food-safety authority has addressed the compound by name in any published document. The gap between "a real finding" and "regulatory silence" is the story, and it deserves the same scrutiny PurityIQ gives the opposite case, where a scary-sounding lab result does move a regulator.
The compound is sucralose-6-acetate, an intermediate formed during the manufacture of sucralose (marketed as Splenda) that also turns up as a trace impurity in the finished sweetener and as a metabolite produced in the human gut. It is not itself an ingredient added to any food.
What just happened
Two developments in 2026 bracket where things stand. On February 17, 2026, the European Food Safety Authority published its formal re-evaluation of sucralose (E 955) as a food additive, covering the toxicology literature on the sweetener published between January 1999 and March 2025, a window that includes the 2023 sucralose-6-acetate paper (EFSA Journal 2026, DOI 10.2903/j.efsa.2026.9854).
EFSA's panel reaffirmed the additive's acceptable daily intake at 15 milligrams per kilogram of body weight per day and concluded sucralose "continues to be safe for consumers for its currently authorised uses." Separately, EFSA declined to confirm safety for a proposed new use in fine bakery wares, citing an unrelated concern about chlorine migrating from the sweetener at high baking temperatures. Neither EFSA's opinion nor its accompanying news release names sucralose-6-acetate.
Four months later, on June 22, 2026, a federal judge in North Carolina dismissed a defamation lawsuit that Splenda's manufacturer, TC Heartland LLC, had filed against Susan Schiffman, the North Carolina State University researcher who led the 2023 study. Judge Catherine C. Eagles ruled that scientific disagreements belong in "the marketplace of ideas and laboratories," not a courtroom, and that both Schiffman and the company had First Amendment protection to state their competing conclusions publicly. The ruling settled a legal dispute over how the study had been characterized; it did not adjudicate whether the underlying lab findings were correct, and no regulator was a party to the case.
How we got here
The 2023 paper (Schiffman, Scholl, Furey, and Nagle, published in the Journal of Toxicology and Environmental Health, Part B) ran a battery of in vitro screening assays on sucralose-6-acetate and, for comparison, on sucralose itself. Two of the assays are directly relevant to genotoxicity: a MultiFlow assay, which screens for chromosome-damaging (clastogenic) activity, and a micronucleus test, which looks for visible chromosome fragments inside cell nuclei after exposure.
Sucralose-6-acetate came back positive in both: the micronucleus test was positive at a concentration of 1,000 micrograms per milliliter after 27 hours of exposure without metabolic activation. That is a genuine signal, cross-corroborated across two independent assay types, not a single flagged result in isolation.
The same paper also ran the Ames test, the bacterial mutagenicity assay regulatory agencies treat as the standard screen for whether a chemical can permanently alter DNA in a way that's heritable across cell generations. For both sucralose-6-acetate and sucralose, the Ames test was negative.
The authors' own conclusion, in their words: "Although sucralose-6-acetate was genotoxic in both the MultiFlow and MN test, DNA damage initiated by sucralose-6-acetate may not lead to permanent alterations in further generations of cells because it is not mutagenic." That line is the study's own authors qualifying their headline finding, not a caveat supplied by the sweetener's defenders.
Other findings from the same paper
Two other findings from the same paper are worth naming plainly, because press coverage of the study mostly left them out. Sucralose-6-acetate inhibited two liver enzymes, CYP1A2 and CYP2C19, that metabolize a range of prescription drugs, a finding relevant to drug-interaction research, separate from the genotoxicity question. And the study's measure of intestinal-barrier disruption (a drop in trans-epithelial electrical resistance, or TEER, in a lab model of the gut lining) only appeared at millimolar concentrations, roughly a thousand times higher than the micromolar range in which the genotoxic signal showed up, and far above anything a person would ingest from food.
The authors also calculated that a single beverage sweetened with sucralose at the maximum EU-approved level could contain enough sucralose-6-acetate to exceed the FDA's threshold of toxicological concern for genotoxic substances, 0.15 micrograms per person per day, by several orders of magnitude. That calculation is based on estimated compound levels in a hypothetical beverage, not a measured human-exposure study, and no regulator has published an evaluation of it.
Where regulators have not addressed it
Most PurityIQ coverage involves the U.S. and EU landing in different places on the same ingredient. Here, on sucralose-6-acetate specifically, neither has landed anywhere. The FDA approved sucralose as a food additive in 1998 (63 Fed. Reg. 16,417, Apr. 3, 1998, codified at 21 CFR § 172.831) and its current page on high-intensity sweeteners still lists sucralose among six approved sweeteners, with no update addressing the 2023 study or sucralose-6-acetate by name.
EFSA's 2026 re-evaluation reviewed genotoxicity literature through March 2025 and reaffirmed sucralose's approval, but its public documents don't mention sucralose-6-acetate either. Two regulators, using different review processes on different schedules, have so far reached the same practical outcome on this one compound: neither has issued a public assessment of it.
That is not proof the finding is unimportant. A genuine, two-assay genotoxic signal in a breakdown product of a sweetener used in thousands of products is the kind of thing regulatory toxicology exists to evaluate.
It is also not proof of a cover-up. EFSA's review window and FDA's original approval don't guarantee either agency has formally assessed sucralose-6-acetate as a distinct substance yet, and a negative Ames test is a real, standard reason a regulator might not treat a clastogenicity signal as an urgent priority.
Context on the source matters too, in both directions. Schiffman has published critically of sucralose before this study. A separate, earlier Schiffman-coauthored study (a 2008 rat study on Splenda's effects on gut microflora) received a formal Expression of Concern from its journal in March 2024, after another researcher flagged apparent figure-integrity problems in the published images on PubPeer.
As of this writing, that concern remains open; the journal states it has not received the data needed to close the investigation, and no correction or retraction has been issued. None of that changes what the 2023 sucralose-6-acetate study's own assays measured. It's relevant to weighing who ran the study, not to discounting the lab data itself.
What the label shows
Sucralose-6-acetate does not appear on any ingredient list. Sucralose itself is listed by name, most often as "sucralose," on diet sodas, powdered drink mixes, sugar-free baked goods, and tabletop sweetener packets sold under the Splenda brand and store brands. No U.S. or EU labeling rule requires disclosure of manufacturing intermediates or gut metabolites that aren't themselves added ingredients, and none currently do.
What PurityIQ shows
This is exactly the kind of record PurityIQ puts in front of you before you're standing in the aisle: the actual study, what it found and didn't find, and what each regulator has and hasn't said about it, cited and dated. You see the record. You decide.
Sources
Schiffman, S.S., Scholl, E.H., Furey, T.S., Nagle, H.T. "Toxicological and pharmacokinetic properties of sucralose-6-acetate and its parent sucralose: in vitro screening assays." Journal of Toxicology and Environmental Health, Part B, 26:6, 307-341 (2023). DOI: 10.1080/10937404.2023.2213903
EFSA Journal 2026. "Re-evaluation of sucralose (E 955) as a food additive." DOI: 10.2903/j.efsa.2026.9854
EFSA News, "EFSA finds sucralose safe when used as currently authorised; cannot confirm safety of extending its use," efsa.europa.eu/en/news/efsa-finds-sucralose-safe-when-used-currently-authorised-cannot-confirm-safety-extending-its (Feb. 17, 2026)
FDA, "High-Intensity Sweeteners," fda.gov/food/food-additives-petitions/high-intensity-sweeteners
Federal Register, "Food Additives Permitted for Direct Addition to Food for Human Consumption; Sucralose," 63 Fed. Reg. 16,417 (Apr. 3, 1998); 21 CFR § 172.831
Retraction Watch, "Judge dismisses Splenda lawsuit, says courts wrong place for research debate" (Jul. 8, 2026)
Retraction Watch, "Paper cited by article at center of lawsuit for criticizing Splenda earns an expression of concern" (Mar. 22, 2024)
Expression of Concern: Abou-Donia, M.B., Schiffman, S.S., et al., "Splenda Alters Gut Microflora and Increases Intestinal P-Glycoprotein and Cytochrome P-450 in Male Rats," Journal of Toxicology and Environmental Health, Part A. DOI: 10.1080/15287394.2024.2321747
As of September 11, 2026.